Mixed Topline Phase 3 Results for PDE5 Inhibitor in Early AD
Summary
Treatment with an investigational PDE5 inhibitor significantly slows clinical decline in patients with early AD not taking standard AD medications, but overall trial results are mixed.
Description from Medscape.
Who is covering this
-
Mixed Topline Phase 3 Results for PDE5 Inhibitor in Early AD
Treatment with an investigational PDE5 inhibitor significantly slows clinical decline in patients with early AD not taking standard AD medications, but overall trial results are mixed.
Comments
Comments need JavaScript.